Michael A. Samuels, MD

home / authors / michael-a-samuels-md

Articles

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Vivek N. Patel, MD;Felix M. Chinea, MD;Deukwoo Kwon, PhD;Gustavo Fernandez, MD;Hanmath J Neboori, MD;Michael A. Samuels, MD;Laura M. Freedman, MD;Nagy M. Elsayad;Donald Weed, MD;Elizabeth Franzmann, MD;Chukwuemeka V. Ikpeazu, MD, PhD;Matthew C. Abramowitz, MD

March 19th 2017

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

$Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?$

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

Michael T. Scott, MD, MBA;Austin Dosch, MD;Nagy Elsayyad, MD;Matthew C. Abramowitz, MD;Arnold M. Markoe, MD;Deukwoo Kwon, PhD;W. Zhao, MD, MS;Michael A. Samuels, MD

September 29th 2015

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.